Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverICCC
HealthcareNCMUSD

ImmuCell Corporation

$0012345678900123456789.0012345678900123456789+0.9%
52w low (est.) $8.95$13.77 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD98.88M
52w range
USD4.52 - USD12.10
Beta
0.57
Sector
Healthcare
Data quality
88/100
Valuation
DCF fair value
USD4.37
Margin of safety
-60.4%
Quality & efficiency
Moat score
36/100
Return on equity
-1.9%
Profit margin
-1.8%
Debt / equity
0.44
Growth & analysts
Revenue growth
+28.4%
Run the 10-point checklist before you buy How these numbers are made

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Valuation

ValueGrowthProfitHealthIncome38QUALITY
Overall Rating
25
Sell
Sell

Derived from filed metrics · High confidence (88% of the inputs available)

Moat Score36
DCF Intrinsic Value
USD4.37-60.4% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD98.88M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+28.4%
Profit Margin
-1.8%
ROE
-1.9%
Debt / Equity
0.44
Beta
0.57
High Growth
vs Healthcare sector:Moat 36 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · ICCC